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ABSTRACT 27 
 28 
Plasticizers added to PVC used in medical devices can be released into patients’ biological 29 
fluids. The substitution of DEHP by alternative plasticizers is essential but their safety must 30 
be demonstrated. DEHP, DEHT and their metabolites were investigated using level 2 OECD 31 
bioassays to screen for in vitro hormonal changes. Differences between the DEHP and DEHT 32 
metabolites were observed. Albeit weak, the hormonal activities of DEHT derived 33 
metabolites, e.g. 5-OH-MEHT, were detected and the results of docking experiments 34 
performed on ERα and AR agreed with the biological results. A co-stimulation of hERα and 35 
hAR was also observed. With regard to steroidogenesis, a 16-fold increase in estrogen 36 
synthesis was measured with 5-OH-MEHT. Therefore, even if DEHT remains an interesting 37 
alternative to DEHP because of its low migration from medical devices, it seems important to 38 
verify that multi-exposed patients in neonatal intensive care units do not have urinary levels 39 
of oxidized metabolites, in particular 5OH-MEHT, suggesting a potential endocrine 40 
disrupting effect. 41 
 42 
 43 
SHORT ABSTRACT  44 
 45 
Plasticizers as DEHT are added to PVC used in medical devices can be released into patients’ 46 
biological fluids. The objective of this study was to investigate the potential endocrine 47 
disrupting effects of DEHT and its metabolites in silico and in vitro. The hormonal activities 48 
of DEHT derived metabolites, e.g. 5-OH-MEHT, were detected and the results of docking 49 
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experiments performed on ERα and AR agreed with the biological results. A co-stimulation of 50 
hERα and hAR and an increase in estrogen synthesis was measured with 5-OH-MEHT 51 
INTRODUCTION 52 
 53 
Plasticizers are used as additives to increase the flexibility and softness of normally rigid 54 
plastics, such as polyvinylchloride (PVC). Plasticized PVC is used in medical devices such as 55 
tubings (infusors, infusion or nutrition lines, extracorporeal circuits) or blood bags. However, 56 
any additives that are not chemically bound to the polymer can be released from the material 57 
into the infused drug solutions or biological fluids and can thereby come into contact with the 58 
patient. This source of exposure presents a general public health concern. Indeed, the 59 
metabolites of these plasticizers are found in the urine of many hospitalized patients, 60 
especially neonates in intensive care units (Mallow et al., 2014; Fischer et al., 2016). Some of 61 
these chemicals are likely to be hazardous for patients, as has been demonstrated for di-(2-62 
ethylhexyl) phthalate (DEHP), which is now classified as CMR 1B (carcinogenic, mutagenic 63 
or toxic for reproduction) under the CLP Regulation due to its effect on reproduction and 64 
fertility (Regulation (EU) 1272/2008). European regulation 2017/745 of 5 April 2017 65 
recommends that the level of DEHP be limited to 0.1% by mass in medical devices 66 
(Regulation (EU) 2017/745). Other plasticizers are recommended to soften PVC, such as di-67 
(2-ethylhexyl) terephthalate (DEHT) (Scenihr, 2015). This additive is interesting because it 68 
has a much lower level of migration from the medical devices into the fluids infused into the 69 
patient than DEHP (Bernard et al, 2015). Moreover, it would be less toxic than DEHP. DEHT 70 
is less active in the induction of peroxisome-proliferation in rats than DEHP and this is 71 
explained by a smaller amount of monoester produced during DEHT metabolism. Moreover, 72 
at equivalent doses, this monoester (MEHT) has a lower cytotoxicity compared to MEHP. At 73 
doses where DEHP altered sexual differentiation, DEHT was inactive (Scenihr, 2015, Eljezi 74 
et al, 2017). However, its migration is not zero and toxicity data are not complete. 75 
Specifically, there is a lack of information regarding the hormonal activities of DEHT and/or 76 
its metabolites resulting from its hydrolysis and oxidation in the body. Indeed, it has been 77 
proven that the oxidized derivatives of DEHT are found in the urine, especially in non-78 
glucuronjugated form regarding to the carboxy derivatives (Barber et al. 1994; Lessmann et 79 
al. 2016). Substitution of DEHP by alternative plasticizers is essential, but the safety of these 80 
substitutes must be demonstrated. In this study we investigated the in vitro effects of DEHP 81 
and DEHT, and their metabolites, using identical bioassays and concentration ranges in order 82 
to check DEHT as a potential substitute. Endocrine disrupting chemicals (EDCs) of estrogen 83 
ER signaling pathways can contribute to adverse health effects on various areas of the body, 84 
such as the nervous system, the heart, breast, reproductive tracts in males and females and 85 
energetic metabolism.  EDCs can affect the endocrine system of an organism through multiple 86 
pathways, such as mimicking natural hormones, antagonizing their action, or modifying their 87 
synthesis, metabolism and transport. In general, the main harmful effects of these compounds 88 
are due to their interaction with members of the nuclear receptor family, including the 89 
estrogen (ERα; ERβ) and the androgen (AR) receptors (Delfosse et al. 2014). Reporter gene 90 
assays are mechanistic and sensitive tools to characterize receptor mediated endocrine activity 91 
and are recommended in the Organisation for Economic Co-operation and Development 92 
(OECD) guidelines (OECD, 2012). The action of estrogen in regulating gene transcription is 93 
mediated through specific estrogen receptors of the nuclear receptor superfamily, such as 94 
receptor α. To test phthalates and their metabolites, human ER α activity was measured using 95 
a stable transfected cell line (Hela 9903) and following OECD guideline TG 455 (OECD 455, 96 
2016). The MDA-kb2 cell line was used for investigating the potential agonist and antagonist 97 
effects on human AR.   98 
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Docking experiments   were used to assess the binding mechanism of DEHT and DEHP and 99 
to determine the potential interactions of these ligands and their metabolites with ERs and 100 
ARs. To study the effect on steroid synthesis, the H295 steroidogenesis assay was performed 101 
in accordance with OECD guideline TG 456 (OECD, 2011). 102 
 103 
The objective of this study was therefore to investigate the potential endocrine disrupting 104 
effects of DEHT (a promising DEHP substitute) and its metabolites on estrogen and androgen 105 
receptors, on steroid synthesis, and to compare them with those of DEHP and its metabolites. 106 
 107 
MATERIAL AND METHODS 108 
 109 
Plasticizers and metabolites 110 
DEHP (Ref: D201154, CAS: 117-81-7) and DEHT (ref: 525189, CAS: 6422-86-2) were 111 
purchased from Sigma Aldrich, France. Primary and secondary metabolites of DEHP and 112 
DEHT were synthesized and characterized by the IMOST team (UMR 1240, INSERM) 113 
Clermont-Ferrand, France. The compounds tested are shown in the Table 1.  The purity of all 114 
our synthetized metabolites and their corresponding intermediates exceeded 95%. 115 
 116 
Preparation of samples 117 
All compounds were dissolved in 100% ethanol and tested over a large range of 118 
concentrations, from 0.02 ng/mL to 200 µg/mL, depending of the assays and the quantity of 119 
synthetized metabolite powder provided by the chemists. In order to avoid a cytotoxic effect 120 
of the vehicle on the cell lines, the maximum concentration of ethanol in the culture medium 121 
was 1%. 122 
 123 
ER and AR Transcriptional Activation Assays 124 
Cell culture 125 
For the cell-based ER-mediated bioassay, stably-transfected hERα-HeLa-9903 cells were 126 
obtained from the Japanese Collection of Research Bioresources (JCRB-N°1318) cell bank. 127 
These cells contain stable expression constructs for human ERα and firefly luciferase. The 128 
latter is under transcriptional control of five Estrogen Response Element (ERE) promoter 129 
elements from the vitellogenin gene. Cells were maintained in Eagles Minimum Essential 130 
Medium (EMEM) without phenol red, supplemented with kanamycin (60 mg/L) and 10% 131 
(v/v) Foetal Bovine Serum (FBS), in an incubator under 5% CO2 at 37°C. Upon reaching 75-132 
90% confluency, cells were subcultured twice (not more than 10 passages) prior to exposure 133 
to the test chemicals. 134 
For the cell-based AR-mediated bioassay, MDA-kb2 cells derived from the MDA-MB-453 135 
breast cancer cell line and stably transfected with the murine mammalian tumor virus 136 
(MMTV-luciferase.neo reporter gene construct, Wilson et al., 2002) were obtained from the 137 
ATCC (N°.CRL-2713). Cells were routinely maintained in Leibowitz-15 (L-15) medium 138 
supplemented with 10% FBS (v/v) in a humidified incubator at 37°C without additional CO2. 139 
Cells were sub-cultured when confluent over a maximum of 10 passages. 140 
Luciferase Assays  141 
The assay for (anti)estrogenic activity was performed in accordance with OECD test guideline 142 
TG455 (OECD, 2016). Prior to experiments, Hela-9903 cells were maintained in culture 143 
medium supplemented with 10% (v/v) DCC-FBS (dextran-coated charcoal stripped serum) 144 
for at least two media-changes. Cells were seeded at a density of 1×10
4
cells per well in 100 μl 145 
of phenol red free culture medium supplemented with 10% DCC-FBS in clear bottom white 146 
luminometer 96-well plates and allowed to attach for 3 h.  147 
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A modified version of the original protocol by Wilson et al. (2002) was used to test 148 
compounds for (anti)androgenic activity (Ermler et al., 2010). Prior to experiments, MDA-149 
kb2 cells were maintained in L-15 medium supplemented with 10% (v/v) DCC-FBS for at 150 
least two media-changes. Cells were seeded at a density of 1×10
4
cells per well in 100 μl of 151 
phenol red free L-15 medium supplemented with 10% DCC-FBS in clear bottom white 152 
luminometer 96-well plates and allowed to attach for 24 h. 153 
After incubation, 50 μl of a 3x dosing medium were added to the wells. The cells were 154 
exposed to the dilution series of the tested chemicals (7 different concentrations of each 155 
sample were tested), to the reference estrogen E2 or reference androgen DHT 156 
(dihydrotestosterone), and to the solvent controls (0.1% v/v ethanol). DHT or E2 (1 nM) was 157 
used as a positive control in the AR or ER agonist assay, respectively. DHT (0.25 nM) or E2 158 
(0.025 nM) was used as a control in order to establish a baseline for co-exposure in order to 159 
screen for AR or ER antagonism, respectively. After 24 h of exposure, the luciferase activity 160 
was determined with Steady Glo assay reagent (Promega) as per the manufacturer's 161 
instructions. 162 
Viability 163 
Cell viability was assessed using a resazurin-based assay performed before the determination 164 
of luciferase activity. After the exposure time and following a 4-h (Hela-9903) or 5-h (MDA-165 
kb2) incubation period with 50 μl/well of 4 µg/mL resazurin (obtained from Sigma-Aldrich) 166 
in PBS, cell proliferation was measured as relative fluorescence units (RFUs) resulting from 167 
the reduction of non-fluorescent resazurin to the fluorescent product resorufin. Fluorescence 168 
was measured at λex = 530 nm and λem = 590 nm on a microplate reader. The average value 169 
for the vehicle control wells was used as 100% and the results for each chemical were 170 
calculated as a percentage. If the test substance showed more than 20% reduction of relative 171 
cell viability, the compound was considered cytotoxic at the tested concentration. 172 
Data analysis 173 
Data points are representative of at least two independent experiments and three replicate 174 
wells per data point in each experiment. All values were corrected for the mean of the 175 
negative control and then related to the positive control, which was set to 100%. Average and 176 
standard deviation of the replicates were calculated. A compound was considered positive if it 177 
increased luminescence more than 10 per cent above the blank baseline in agonist mode, or 178 
decreased luminescence by more than 20 per cent of the maximal signal in antagonist mode. 179 
 180 
H295R Steroidogenesis assay 181 
 Cell culture and treatment 182 
Cell culture conditions and media preparation were conducted in accordance with OECD test 183 
guideline 456 (OECD, 2011). Human H295R adrenocortical carcinoma cells (ATCC CRL-184 
2128) were expanded for 5 passages and frozen in batches in liquid nitrogen. Prior to 185 
conducting steroidogenesis evaluation, batches of H295R cells were thawed and passed at 186 
least 4 times. The maximum passage number used for steroidogenesis evaluation was 10. 187 
Cells were routinely grown at 37°C under a 5% CO2 atmosphere in 75 cm
2
 culture flasks 188 
containing 12 mL DMEM/Ham’s F12 culture medium mixture (Gibco 11039021) 189 
supplemented with 1% ITS+ premix (BD Bioscience; 354352) and 2.5% Nu-Serum (BD 190 
Bioscience; 355100). For subculturing, the H295R cells were washed three times with PBS, 191 
detached using trypsin/EDTA (0.25%/0.05% (v/v) in Hank’s Balanced Salt Solution (HBSS)) 192 
and seeded in a 1:3 ratio. For testing, 1 mL cell suspension containing 3 × 10
5
 cells was 193 
seeded in each well of a 24-well plate. After 24 h (50-60% confluence), the medium was 194 
refreshed and compounds dissolved in Ethanol (EtOH) were added. Exposures were 195 
performed in triplicate with a final concentration of the solvent carrier of 0.1%. Positive 196 
controls, 10 µM forskolin (FOR) and 1 µM prochloraz (PRO), were included on each plate. 197 
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Following 48 h of chemical treatment, media was removed, split into 2 vials of approximately 198 
500 µl media each, and stored at -80°C prior to 17β-estradiol (E2) and testosterone (T) 199 
quantification.  200 
Viability  201 
After exposure, the cells were incubated with resazurin solution to test for viability. 202 
Fluorescence was measured using a Chameleon multi-detection microplate reader (Hidex 203 
Instruments Inc.). Exposures showing a decrease in cell viability were excluded from 204 
hormone analysis. 205 
Release of hormones 206 
Enzyme linked immunosorbent assays (ELISA) were used to directly quantify testosterone 207 
and 17β-estradiol from aliquots of the medium. The ELISA kits (KGE010, KGE014) were 208 
purchased from Bio-Techne (R&D systems Europe, France). According to the manufacturer’s 209 
data, the sensitivity of the testosterone assay was 0.030 ng/mL, and the intra and inter-assay 210 
coefficients of variation were 4.0% and 5.6%, respectively. The sensitivity of the 17β-211 
estradiol assay was 4.84 pg/mL, and the intra- and inter-assay coefficients of variation were 212 
6.0% and 7.1%, respectively. The absorbance was determined at a wavelength of 450 nm 213 
using a Tecan (BioRad) microplate reader.  214 
 215 
Data analysis 216 
Fold changes in steroids levels in the H295R steroidogenesis assay were calculated by 217 
comparing the mean steroid levels of the solvent control versus the mean steroid levels in 218 
medium of H295R cells exposed to the compound under investigation. 219 
Statistical analysis 220 
Obtained data were statistically analyzed using GraphPad Prism 6.00 (GraphPad Software 221 
Incorporated, San Diego, CA, USA). Descriptive statistical characteristics (arithmetic mean, 222 
minimum, maximum, standard deviation and coefficient of variation) were evaluated. One-223 
way analysis of variance (ANOVA) and the Dunnett´s multiple comparison test were used for 224 
statistical evaluations. The level of significance was set at ***p < 0.001; **p < 0.01 and *p < 225 
0.05. 226 
 227 
Docking studies 228 
 229 
The docking of the compounds under evaluation was performed using the crystallographic 230 
coordinates 2iog for ERα (Dykstra et al., 2007) and 2am9 for the AR (Pereira de Jesus-Tran et 231 
al., 2006). It should be noted that the docking of the compounds was performed irrespective of 232 
the pharmacological type of ligand crystallized with the receptor, which was only chosen on the 233 
basis of the structural proximity of the crystallized ligand to the phthalate derivatives, using the 234 
lowest possible resolution. As the receptors under scrutiny are nuclear receptors, there is an 235 
adaptation of the receptor to the ligand which has not been investigated here and mostly prevents 236 
conclusions being made on the pharmacological effect of the compounds on the basis of these 237 
docking experiments. The co-crystallized ligand was extracted and used to define the binding 238 
site as a sphere of 10 Å using GOLD (Jones et al., 1997). The charges of the ligands and 239 
receptors were assigned using the Gasteiger-Hückel method and the geometry of the each ligand 240 
configuration was optimized with the maximin2 protocol of the Sybyl 6.9.1 molecular modeling 241 
software. 30 solutions were generated for each compound and the number of poses of each 242 
cluster gave a rough idea of the particular stability of the complex compared to the other clusters. 243 
The final docking results were the most representative conformation of each cluster, in so far as 244 
it was possible to define a sensible common placement. The central aromatic ring was the 245 
primary structure taken into account to define a cluster. The long and flexible chains of the 246 
compounds were mostly discounted at this stage, with the exception of the oxygen atoms. 247 
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 248 
RESULTS 249 
Agonist or antagonist activities on human nuclear receptors in gene reporter assays 250 
Transcriptional activity of human ERα 251 
Agonist or antagonist activities on hERα were measured in the absence or presence of E2. 252 
Neither DEHT nor DEHP (supplementary data, figure 1) were active on hERα. The same 253 
conclusion can be drawn for their corresponding mono-esters (in terms of agonist or 254 
antagonist activities) using a large non- cytotoxic concentration range (up to 20 µg/mL), with 255 
the exception of a weak antagonist activity of MEHP at the highest concentration but without 256 
any cytotoxicity (figure 1).  257 
With regard to the hydroxylated monoesters (figure 1), 5-OH-MEHT induced an agonist 258 
effect on ERα at the highest concentration and a synergic concentration dependent effect in 259 
the presence of E2 at 0.2 and up to 20 µg/mL, while 5-OH-MEHP was an antagonist at the 260 
highest concentration without any cytotoxicity.  261 
Oxo–derived monoester metabolites were equivalent partial antagonists of ERα with a 262 
concentration dependency effect (2 – 20 µg/mL) without cytotoxicity (figure 1). 5-Cx-MEHT 263 
and 5-Cx-MEHP were not active in the transcriptional assay irrespective of the activity 264 
studied.  265 
 266 
Transcriptional activity of human AR  267 
Neither DEHT nor DEHP induced agonist or antagonist activities on AR over a large non-268 
cytotoxic concentration range (up to 20 µg/mL) (supplementary data, figure 1). The same 269 
conclusion can be drawn with regard to the respective monoester and derived metabolites 270 
(figure 2).  271 
Concerning DEHT metabolites, 5-OH-MEHT was the only metabolite active on AR, with a 272 
synergic concentration dependent effect (0.2 to 20 µg/mL) when cells were co-treated with 273 
DHT. It should be noted that, under our experimental conditions, oxo–derived or carboxy–274 
derived monoester metabolites of both phthalates had no effect on AR transcriptional activity.  275 
 276 
Docking experiments 277 
The co-crystallized ligands of the investigated receptors (compound 11F for ERα and 278 
testosterone for AR) were docked to validate the protocol. Both were very close to their 279 
crystallographic position and a high majority of their 30 conformations were in this single 280 
conformation. For AR, testosterone was less univocal in its binding mode than the other co-281 
crystallized molecule, as it could be placed in either its crystallographic position for about two 282 
thirds of the poses, or exchange its extremities for the remaining third. Both conformations 283 
were nonetheless strongly bound to the receptor via hydrogen bonds with Thr 877 and Arg 284 
752. As expected, the second hydrogen bond formed between the hydroxyl group and Asn 285 
705 was only found in its crystallographic position. For ERα, the crystallographic 286 
conformation was found nearly exclusively, with 27 solutions out of 30. The three other 287 
positions were mostly different orientations of the side chains, and in one case was an 288 
inversion of the positions of the chains on each side of the amide linkage. The strong ionic 289 
interaction with Asp 351 was maintained in all but two cases, while the hydrogen bonds with 290 
Glu 353 and Arg 394 were only lost in a single case of chain inversion. These results agree 291 
with those obtained by Delfosse et al., 2014. 292 
MEHT binds sufficiently with ERα, irrespective of the configuration of its branched ester 293 
chain. The free acid interacts strongly with Arg 334, putting the benzene ring in a good 294 
position for stacking with the nearby Phe 404. These are the two main interactions of the co-295 
crystallized ligand. The other end of the compound is less fixed and fluctuates in the wide 296 
binding site, as the ester is much smaller than the original ligand. There is, therefore, a wide 297 
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range of conformations from a single common point of interaction rather than a well-defined 298 
cluster, which may indicate that, apart from this single ionic interaction, MEHT is not able to 299 
find a favorable binding environment. MEHT binds well with AR with about three-fourths of 300 
the 30 solutions in a single cluster irrespective of the configuration. Again, the free acid forms 301 
a strong interaction with Arg 752, and it is most probable that the nearby Phe 764 would 302 
reorient slightly to form a stacking. Quite unsurprisingly, these are the main interactions of 303 
testosterone. The ester chain is mostly rolled up toward the aromatic ring, in a conformation 304 
that is not very energetically favorable for the interaction with the receptor (Figure 3).  305 
5-OH-MEHT is placed in ERα in much the same way, with a conserved interaction with Arg 306 
394 at the acid end. The hydroxyl group at the other end forms a near constant hydrogen bond 307 
with Thr 347. It forms a fan that is bound by the acid and spreads at the ester end. On the 308 
contrary, in AR, 5-OH-MEHT occupies only two positions, both very close to that of its 309 
parent molecule and forming interactions at both extremities, as in ERα. While MEHT is able 310 
to fit into the cavity of the androgen receptor and form an ionic interaction with Arg 752, it 311 
lacks the rear side interaction formed by testosterone, and its long ester chain is not stabilized 312 
in a particular conformation. On the contrary, the 5-hydroxylated congener, while assuming 313 
the same position for the central block and the interaction with Arg 752, also keeps a 314 
hydrogen bond at the rear, formed by its hydroxyl moiety either with Asn 752, Thr 877 or 315 
both. Keeping in mind that the side chains of the residues were kept rigid, it is most probable 316 
that the hydroxyl is binding to both residues in a mode very similar to that observed for the 317 
natural ligand (Figure 4). 318 
 319 
Steroids synthesis assays  320 
The H295 steroidogenesis assay was performed with derived plasticizer metabolites in order 321 
to detect substances which affect the production of E2 or testosterone and to understand if an 322 
indirect mechanism, such as enzyme inhibition or induction, could occur. Figure 5 shows 323 
statistical fold changes in hormone synthesis with the tested metabolites.  324 
Estradiol synthesis 325 
MEHT and MEHP were weakly active, with for MEHP a significant change between 2 and 326 
40 µg/mL and a 6_fold induction at 40 µg/mL for MEHP.  327 
Unfortunately MEHT was cytotoxic for the cells above 10 µg/mL. Hydroxylated derived 328 
metabolites were more potent, with a concentration dependent increase in estradiol synthesis. 329 
A maximum 12-fold increase was seen at 80 µg/mL. This significant effect started at a lower 330 
concentration with 5-OH-MEHP (0.2 µg/mL) compared to 10 µg/mL with 5-OH-MEHT. 331 
Oxo-derived monoesters were the most active metabolites, with an induction starting at 332 
10 µg/mL, and reaching a 14 to 16-fold induction at the highest concentration (80 µg/mL). 333 
Carboxy-derived metabolites started to be significant agonists at 40 µg/mL, but with only a 334 
weak effect (around 2-fold). 335 
Testosterone synthesis  336 
A similar and statistically significant decrease of testosterone (2-fold) was observed with OH-337 
derived metabolites. 5-OH-MEHT had an effect at a lower concentration (20 µg/mL) than 5-338 
OH-MEHP (40 µg/mL). It should be noted that at 10 µg/mL, MEHT also decreased 339 
testosterone synthesis. Figure 3 shows the same tendency with the oxo-derived metabolites at 340 
40 and 80 µg/mL, with a change observed at a lower oxo-MEHT concentration (10 µg/mL 341 
instead of 40 µg/mL with oxo-MEHP). 5-Cx-derived metabolites had no effect on 342 
testosterone synthesis.  343 
 344 
 345 
DISCUSSION  346 
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We used the reporter gene assays recommended by the OECD (level 2) to screen for 347 
hormonal activities, with the corresponding absence or presence of the reference hormone, 348 
and to test the agonist, antagonist and synergic properties of DEHP and DEHT and their 349 
metabolites (Sataya et al., 2012). The compounds were also docked to assess their binding 350 
affinity with ER and AR. 351 
 352 
Impact on sexual hormones  353 
DEHP and DEHP metabolites 354 
We found that, when a transcriptional effect was observed on ERα, it was mainly due to the 355 
oxidized metabolites of DEHP, such as 5-OH-MEHP. Indeed, 5-OH-MEHP was an antagonist 356 
at the highest concentration, with the effect being more pronounced when the cell line was 357 
exposed to non-cytotoxic concentrations. Our data on the absence of estrogenic agonist 358 
activity with DEHP agree with Shen et al (2009), Jobling et al, 1995 and Zacharewski et al., 359 
1998 who showed no ER transactivity and no capacity for DEHP to compete with E2–ER 360 
binding in vitro. In contrast, Takeuchy et al (2005), who tested DEHP and its corresponding 361 
monoester MEHP, observed a weak activation of hERα with 5.5 µM DEHP in a transiently 362 
transfected cell line (CHO K1 cells). Our data do not agree with the study by Engel et al 363 
(2017) who demonstrated, using stably transfected human embryonic cells (HEK293), that 364 
DEHP metabolites were never active up to a concentration of 100 µM. Their data also proved 365 
that the absence of an effect was not due to a lack of cellular uptake of the metabolites in their 366 
model. Furthermore, Engel et al. only noted an inhibition with DEHP when using a co-367 
treatment of E2 at a very high concentration (100 µM). More recently, Yang et al (2018) used 368 
nanoMolar concentrations to demonstrate that MEHP can trigger the proliferation of cervical 369 
cancer cells via the activation of the G-protein coupled estrogen receptor (GPER) rather than 370 
ERα. These discrepancies in the literature data could be due to the different cell lines used and 371 
to differences in experimental setups, such as the reporter gene constructs (Jones et al., 1999). 372 
It is important to note that DEHP has to be metabolized to MEHP and its derived metabolites 373 
in order to be bioactive both in vivo or in vitro (Gray et al., 1986; Koch et al., 2005; 374 
Chauvigne et al., 2009) and the differences observed in in vitro models may also be due to the 375 
presence or absence of enzymatic activities in the cell lines used. Moreover, DEHP is known 376 
to be greatly metabolized in vivo after oral exposure, suggesting a low probability of a direct 377 
tissue exposure to the parent substances. Furthermore, long chain phthalates are converted to 378 
oxidized metabolites by hepatic enzymes, then at the molecular level the adverse effects of 379 
phthalates may be in fact due to effects mediated by phthalates metabolites (Kluwe, 1982). 380 
Concerning the transcriptional activity of AR, our data agree with those found by Engel et al. 381 
(2017) where the authors did not observe any agonist effect on AR in the presence of DEHP 382 
or its derived metabolites up to a concentration of 25 µM. However, the same authors 383 
observed an AR inhibition at 50 µM, a two-fold higher concentration compared to our study. 384 
This could be due to some cytotoxic response not displayed in the cytotoxicity assay used. A 385 
crucial parameter when performing in vitro tests is the use of the proper concentrations in 386 
order to avoid false positives data. It is essential to test substances at non-cytotoxic 387 
concentrations, especially when an antagonist effect is observed.  388 
In the study by Shen et al. (2009), both mixed androgenic and anti-androgenic effects were 389 
observed with DEHP on the same cell line (MDA-kb2), with an EC50 (concentration which  390 
gives a half-maximum response) or IC50 (concentration which inhibits  the response by half) 391 
exceeding 10
-4
 M, which is a very high concentration. Araki et al. (2005) also demonstrated 392 
an antagonist effect of DEHP on AR. However, this was not seen by Kruger et al. (2008). 393 
Again the sensitivity of the cell line and consequent variant sensitivity could be at the origin 394 
of the differences between the data.  It should be noted that the cell line we used was probably 395 
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not able to metabolize DEHP until ultimate active metabolites such as hydroxylated/oxidized 396 
metabolites as effect in reporter gene was observed only with DEHP metabolites. 397 
 398 
Using the steroidogenesis synthesis assay, which gives information on another mode of ED 399 
action (not genomic), we have shown that MEHP is also active at 40 µg/mL, with an increase 400 
of E2 and a decrease of testosterone. The effect was even more pronounced with its derived 401 
hydroxylated monoester (5-OH and 5-oxo-MEHP). The effects observed at the concentration 402 
range used in this study agree with those seen by Mankidy et al. (2013), who demonstrated 403 
that hormone synthesis was affected by DEHP concentrations of 10 µg/mL, resulting in a 404 
greater production of E2 (4-fold) and a concurrent reduction of testosterone concentration. 405 
However, they did not test DEHP metabolites. In our study, the induction observed with 406 
DEHP metabolites was even more pronounced (up to 15-fold). Interestingly, Desdoits-407 
Lethimonier et al. (2012) used human testis explants to demonstrate that phthalates affect 408 
human testis steroidogenesis but that DEHP has to be metabolized to MEHP to be bioactive. 409 
MEHP metabolites, including 5-OH-MEHP, also display anti-androgenic activities. 410 
Production of all testosterone precursors of the 4 and 5 pathways was inhibited by MEHP. 411 
Using NCI-H295 cells over concentration ranges found in men in recent epidemiological 412 
studies, DEHP and MEHP have been shown to also reduce testosterone production in vitro 413 
after 48 h, associating phthalate exposure with the impairment of the androgynous status.  414 
 415 
 416 
DEHT and DEHT metabolites  417 
5-OH-MEHT showed an agonist effect at the highest concentration and, interestingly, a 418 
synergism in the presence of E2, with a concentration dependency effect on ER (from 0.2 up 419 
to 20 µg/mL). However, when expressed as Eq/L E2 (supplementary data, figure 2), the 420 
agonist effect of 5-OH-MEHT is weak, with a relative potency 3.5 x 10
-6
 fold lower than E2.  421 
Furthermore, only 5-OH-MEHT was active on AR, with again a synergic concentration 422 
dependent effect when cells were co-treated with DHT. Using the Wilson model, reporter 423 
gene induction may be triggered via GR or AR activation (Wilson et al, 2002). However, as a 424 
synergic effect was observed with DHT, we can conclude that AR was involved.  425 
To date, co-stimulation by 5-OH-MEHT and E2 or DHT has never been observed in in vitro 426 
studies. With regard to steroid synthesis, estrogen synthesis could increase up to 16-fold and 427 
Cx derived metabolites had a very weak effect. In terms of estrogen synthesis, the rank order 428 
potency was as follows: MEHT < corresponding OH metabolite < corresponding OXO 429 
metabolite. With regard to testosterone levels, a weak but significant decrease was noted with 430 
no difference between the metabolites.  431 
Concerning DEHT, we lack information on this endpoint. However, it is interesting to note 432 
that DEHT metabolites were more active in the steroidogenesis assay compared to DEHP 433 
metabolites. Experiments are ongoing in the lab on the effect of DEHT and/or its metabolites 434 
on the aromatase level which could be involved in the changes in estradiol level as 435 
demonstrated in vitro by Lovekamp and Davis (2001) with MEHP. 436 
 437 
Docking 438 
Efforts were limited to the estrogen receptor α due to the fact that ERβ has a low number of 439 
different residues in its binding site, the most notable of which is a valine in place of a leucine 440 
at position 487, at the entry of the pocket. However, the overall difference is a slight 441 
movement of the C-terminal loop-helix-loop assembly, resulting in a slightly different spatial 442 
arrangement of this residue. These observations are consistent with those of Defosse et al. 443 
2014. The phthalate metabolites were further investigated due to their potential for hydrogen 444 
bond formation with the free acid group. It should be kept in mind that docking only 445 
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investigates the direct interactions with the receptor, without taking into account accessibility 446 
to the binding site. In particular, the high flexibility of MEHT’s long ester chain may mask 447 
the free acid or get entangled in the entry of the pocket and inhibit its binding. Both 448 
phenomena are beyond the scope of the in silico tool employed here, and may thus explain the 449 
observed differences between the docking results and the biological results for MEHT. The 450 
monoesters, MEHT and MEHP, behave differently. MEHT strongly binds to the arginine of 451 
both receptors but with no anchorage; its second ester adopts a large number of possible 452 
conformations in the pocket, which may relate to a poor fit for the binding sites despite the 453 
ionic bond with the arginine. MEHP has no interaction with ER; the free acid is clearly being 454 
screened by the large ester chain. The same is true for AR. As a result, this metabolite has 455 
apparently a very low possibility of being a ligand for ERα or AR. Among the oxidized 456 
metabolites, the 5-OH-MEHT is able to bind quite well to both receptors, with well-kept 457 
interactions at both the free acid, pointing toward an arginine, and the ester chain hydroxyl 458 
group, which readily forms hydrogen bonds. It also fits into both receptors in a single 459 
conformation. Inversely, the other metabolites of this series do not show the same binding 460 
capacity and have several different conformations (data not shown). The MEHP congener 461 
behaves differently, with 4 conformations in ER and 2 in AR. The 5-oxo-MEHT and -MEHP 462 
can both bind to the two studied receptors in two or more different conformations, even 463 
lacking any full interaction for the latter in AR. The addition of another acid group on the 464 
ester chain is not optimal. 5-cx-MEHT is able to bind to the arginine of both receptors but not 465 
in a well-defined conformation. There is a slightly better docking with AR than ER. 5-cx-466 
MEHP forms a large number of small size clusters in the two receptors studied, indicating an 467 
unstable docking and therefore hinting at a low potential affinity, if any. Overall, the best 468 
binder is clearly 5-OH-MEHT, which readily binds to ERα and AR in a mode very similar to 469 
that of the natural ligands. 470 
 471 
 472 
In vitro data versus biomonitoring values 473 
In neonatal intensive care units (NICU), neonates are particularly exposed to plasticizers 474 
released from PVC medical devices. Biomonitoring studies have allowed the measurement of 475 
the urinary levels of DEHP metabolites in neonates hospitalized in these units. Strommen et 476 
al. (2016) showed that the urinary concentration of 5-oxo and 5-OH-MEHP could reach 477 
1 μg/mL. The cohort studied by Demirel et al. (2016) presented even higher values with 478 
maximum limits in the order of 5 μg/mL for these two oxidized metabolites. Our study shows 479 
that at these concentrations there is an antagonistic effect on estrogen receptors. Moreover, the 480 
effects of 5-OH-MEHP on the synthesis of estradiol are observed from 0.2 μg/mL, which is 481 
close to the median concentration observed in these newborns. In intensive care, 482 
extracorporeal membrane oxygenation (ECMO) is one of the primary medical situations that 483 
exposes patients to DEHP for several days or even weeks. In particular, a study in adults has 484 
shown that patients on ECMO had urinary 5-OH-MEHP concentrations of more than 5 μg/mL 485 
and blood concentrations of more than 0.8 μg/mL (Huygh et al., 2015). 486 
Concerning DEHT, there is currently no biomonitoring study performed in a medical 487 
environment while this plasticizer was identified in medical devices used in pediatric 488 
intensive care units (Malarvannan et al., 2019). The study by Lessmann et al. (2017) gives 489 
urinary concentrations of DEHT metabolites in a population of children aged 4 to 17 years. 490 
The maximum levels observed were 0.06 μg/mL for 5-oxo-MEHT, 0.18 μg/mL for 5-OH-491 
MEHT and 0.34 μg/mL for 5-cx-MEHT. Even if the median concentration of 5-OH-MEHT 492 
was much lower (0.045 μg/mL), the maximum concentration observed corresponds to the 493 
concentration showing the first synergistic effect with E2 on hER alpha and agonist effects on 494 
AR receptors. Therefore, the question arises regarding the level of exposure of patients using 495 
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medical devices containing DEHT and the potential endocrine disrupting effect. The ongoing 496 
biomonitoring study under the Armed-Neo project should provide us with the necessary 497 
elements to further assess the risk. Experiments are on-going to check hormonal activities of 498 
neonatal urine extracts.  499 
In this study, the biological effects of single tested metabolites appear to be weak and 500 
far less potent than natural hormones. However, an observed synergic effect at low levels 501 
must be taken into account and not be considered as insignificant as the human population is 502 
continuously exposed to complex mixtures of chemicals in the presence of natural hormones 503 
(Ghisary et al., 2009; Kortenkamp et al., 1998). Therefore in vitro experiments are important 504 
in order to monitor the effects of metabolites and can be relevant to in vivo situations, at least 505 
for people with higher exposure levels, such as neonates exposed to medical devices in 506 
neonatal intensive care units (Calafat et al., 2004). 507 
However, it is reassuring that the main oxidized metabolite found in the urine of 508 
newborns exposed to DEHP or DEHT is the carboxylated metabolite. Our work highlights 509 
that 5-cx-MEHP and 5-cx-MEHT derivatives are not active in vitro whatever the hormonal 510 
activity studied. Indeed, biomonitoring studies in neonates exposed to DEHP by medical 511 
devices have shown an urinary level of 5OH-MEHP of 5 to 15% whereas 5-cx-MEHP 512 
accounts for 60 to 83% of all metabolites (Strommen et al., 2016, Stroustrup et al, 2018). In 513 
adults, 5-OH-MEHP is present in greater quantity than 5-cx-MEHP (around 40% of each of 514 
these two metabolites, 20% of 5-Oxo-MEHP). Concerning the metabolites of DEHT, a study 515 
on a children population not exposed to medical devices has shown a similar distribution in 516 
favor of 5-cx-MEHT (85% 5-cx-MEHT, 9% 5- OH-MEHT and 6% 5-oxo-MEHT) (Lessmann 517 
et al. 2017). 518 
 519 
 520 
CONCLUSION 521 
This study presents biological hormonal activities of the derived metabolites of DEHP and 522 
DEHT, involving carboxy-metabolites, and demonstrates, at a molecular level, the different 523 
mechanisms of action of phthalate metabolites compared to the respective parent molecules, 524 
as well as the differences between DEHP and DEHT. The effects observed were more 525 
important for steroidogenesis synthesis, suggesting an indirect mode of action for DEHP or 526 
DEHT metabolites. This is the first time that a co-stimulation of hERα and hAR has been 527 
observed with 5-OH-MEHT. In silico results for ERα and AR are in good agreement with the 528 
observed biological results for 5-OH-MEHT and MEHP, while the docking of MEHT is less 529 
conclusive. This compound maintains an interaction with the arginines but lacks other 530 
interactions, and its ester is unfavorably constrained to fit into the pockets.  531 
These data, taken together with the phthalate exposure levels of neonates via medical devices, 532 
demonstrate the relevance and the sensitivity of bioassays to detect hormonal activities, as 533 
recommended by the level 2 OECD guidelines. They also show the importance of monitoring 534 
the hormonal activities, such as antagonism or synergism, at the molecular level and their use 535 
as a screening step to better protect vulnerable populations to DEHP substitutes. 536 
Our study shows that investigations concerning the hazard of DEHT during exposition of 537 
neonates to medical devices must be monitored before attesting to its safety. Several elements 538 
play in favor of this plasticizer as an alternative to DEHP: its weak diffusion towards the 539 
liquids in contact with the medical devices limiting the exposure of the patients, its less 540 
toxicity compared to the DEHP (cytotoxicity, carcinotoxicity, reprotoxicity). However, the 541 
results of our study lead to caution with respect to the potential endocrine disrupting effect of 542 
the hydroxylated metabolite (5-OH-MEHT). It should be ensured that the urinary levels of 543 
this metabolite are lower than the concentrations that have shown co-stimulation of estrogen 544 
receptors, and an increase in estrogen synthesis. 545 
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Figure Legends  763 
 764 
Figure 1: Estrogen receptor agonism (ER) and antagonism (anti-ER, in the presence of 0.025 765 
nM E2) with DEHT- and DEHP-metabolites in Hela-9903 transcriptional activation assays. 766 
Cell viability was evaluated by the resazurin assay. Data represents mean ± standard deviation 767 
of six data points (two experiments each in triplicate). 768 
The dotted lines (.....) highlight 10% 1nM E2 normalized RTA (Relative Transcriptional 769 
Activity) in the agonist mode or 80% 0.025nM E2 normalized RTA in the antagonist mode, as 770 
a threshold for categorizing positive data. 771 
 772 
Figure 2: Androgen receptor agonism (AR) and antagonism antagonism (anti-AR, in the 773 
presence of 0.25 nM DHT) with DEHT- and DEHP-metabolites in MDA-kb2 transcriptional 774 
activation assays. Cell viability was evaluated by the resazurin assay. Data represents mean ± 775 
standard deviation of six data points (two experiments each in triplicate). 776 
The dotted lines (.....) highlight 10% 1nM DHT normalized RTA (Relative Transcriptional 777 
Activity) in the agonist mode or 80% 0.25nM E2 normalized RTA in the antagonist mode, as 778 
a threshold for categorizing positive data. 779 
 780 
Figure 3: Docking of MEHT in ER (left panel, reference ligand in yellow) and AR (right 781 
panel, reference ligand in orange) 782 
 783 
Figure 4: Docking of 5-OH-MEHT in ER (left panel, reference ligand in yellow) and AR 784 
(right panel, reference ligand in orange) 785 
 786 
Figure 5: Changes in hormone levels (Estradiol and Testosterone) in H295R cell medium after 787 
48 h of exposure to DEHT- and DEHP-metabolites. Changes in hormone levels are expressed 788 
taking into account the effect of the ethanol solvent (mean ± SD, n=3). Statistical significance 789 
*p<0.05, **p<0.01 and ***p<0.001. 790 
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DEHP and its metabolites DEHT and its metabolites 
DEHP: di-(2-ethylhexyl)phthalate 
 
 
 
 
 
DEHT or DEHTP: di-(2-ethylhexyl)terephthalate 
 
 
 
 
MEHP: mono-(2-ethylhexyl)phthalate 
 
 
 
MEHT or MEHTP: mono-(2-
ethylhexyl)terephthalate 
5-oxo-MEHP or MEOHP: mono-(2-ethyl-5-
oxohexyl)phthalate      
 
                                       
 
5-oxo-MEHT or MEOHTP: mono-(2-ethyl-5-
oxohexyl)terephthalate             
5-OH-MEHP or MEHHP: mono-(2-ethyl-5-
hydroxyhexyl)phthalate             
5-OH-MEHT or MEHHTP: mono-(2-ethyl-5-
hydroxyhexyl)terephthalate            
18 
 
5-cx-MEHP or MECPP: mono-(2-ethyl-5-
carboxypentyl)phthalate             
 
 
 
 
 
5-cx-MEHT or MECPTP: mono-(2-ethyl-5-
carboxypentyl)terephthalate             
 
 811 
Table 1: Structures and denomination of DEHP, DEHT and metabolites  812 
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Figure 1 828 
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 829 
Figure 2 830 
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Figure 3 835 
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 841 
Figure 4 842 
 843 
 844 
 845 
 846 
 847 
 848 
Asn 705 
Thr 877 
Phe 764 
Arg 752 
Arg 394 
Asp 351 
Thr 347 
Phe 404 
Asp 351 
Thr 347 
Phe 404 
Arg 394 
Asn 705 
Thr 877 
Phe 764 
Arg 752 
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 849 
Figure 5 850 
 851 
 852 
 853 
23 
 
 854 
 855 
 856 
Figure 1s: Estrogen or androgen receptor agonism and antagonism with DEHT and DEHP in Hela-9903 857 
or MDA-kb2 transcriptional activation assays, respectively. Cell viability was evaluated by the 858 
resazurin assay. Data represents mean ± SD of two independent experiments (performed in 859 
triplicate). 860 
The dotted lines (.....) highlight 10% 1nM E2 or 1nM DHT normalized RTA (Relative Transcriptional 861 
Activity) in the agonist mode or 80% 0.025nM E2 or 0.25nM DHT normalized RTA in the antagonist 862 
mode, as a threshold for categorizing positive data. 863 
 864 
  865 
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 866 
 867 
 868 
 869 
Figure 2s: Dose response of the estrogen reference (estradiol, E2) in Hela-9903 transcriptional 870 
activation assays for the determination of estradiol equivalent activity of phthalate metabolites 871 
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